Logo image of BMA.OL

BYGGMA ASA (BMA.OL) Stock Fundamental Analysis

OSL:BMA - Euronext Oslo - NO0003087603 - Common Stock - Currency: NOK

16.9  -0.1 (-0.59%)

Fundamental Rating

2

BMA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 19 industry peers in the Building Products industry. BMA may be in some trouble as it scores bad on both profitability and health. BMA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

BMA had negative earnings in the past year.
In the past year BMA had a positive cash flow from operations.
Each year in the past 5 years BMA has been profitable.
BMA had a positive operating cash flow in each of the past 5 years.
BMA.OL Yearly Net Income VS EBIT VS OCF VS FCFBMA.OL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M 200M 300M 400M

1.2 Ratios

Looking at the Return On Assets, with a value of -4.81%, BMA is doing worse than 83.33% of the companies in the same industry.
BMA has a worse Return On Equity (-13.53%) than 72.22% of its industry peers.
Industry RankSector Rank
ROA -4.81%
ROE -13.53%
ROIC N/A
ROA(3y)8.09%
ROA(5y)6.56%
ROE(3y)23.89%
ROE(5y)17.99%
ROIC(3y)N/A
ROIC(5y)N/A
BMA.OL Yearly ROA, ROE, ROICBMA.OL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 10 20 30 40 50

1.3 Margins

In the last couple of years the Profit Margin of BMA has remained more or less at the same level.
In the last couple of years the Operating Margin of BMA has declined.
BMA has a better Gross Margin (48.29%) than 83.33% of its industry peers.
In the last couple of years the Gross Margin of BMA has remained more or less at the same level.
BMA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 48.29%
OM growth 3Y-78.5%
OM growth 5Y-52.64%
PM growth 3Y-23.32%
PM growth 5Y-0.59%
GM growth 3Y-1.72%
GM growth 5Y-0.82%
BMA.OL Yearly Profit, Operating, Gross MarginsBMA.OL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 10 20 30 40 50

More info and screens

1

2. Health

2.1 Basic Checks

BMA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BMA has about the same amount of shares outstanding.
Compared to 5 years ago, BMA has less shares outstanding
Compared to 1 year ago, BMA has an improved debt to assets ratio.
BMA.OL Yearly Shares OutstandingBMA.OL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
BMA.OL Yearly Total Debt VS Total AssetsBMA.OL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 1B 2B 3B

2.2 Solvency

Based on the Altman-Z score of 1.21, we must say that BMA is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of BMA (1.21) is worse than 72.22% of its industry peers.
The Debt to FCF ratio of BMA is 20.26, which is on the high side as it means it would take BMA, 20.26 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 20.26, BMA is doing worse than 66.67% of the companies in the same industry.
BMA has a Debt/Equity ratio of 0.95. This is a neutral value indicating BMA is somewhat dependend on debt financing.
BMA has a worse Debt to Equity ratio (0.95) than 72.22% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.95
Debt/FCF 20.26
Altman-Z 1.21
ROIC/WACCN/A
WACC8.16%
BMA.OL Yearly LT Debt VS Equity VS FCFBMA.OL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M 400M 600M 800M 1B

2.3 Liquidity

BMA has a Current Ratio of 0.72. This is a bad value and indicates that BMA is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.72, BMA is not doing good in the industry: 83.33% of the companies in the same industry are doing better.
A Quick Ratio of 0.37 indicates that BMA may have some problems paying its short term obligations.
BMA has a worse Quick ratio (0.37) than 83.33% of its industry peers.
Industry RankSector Rank
Current Ratio 0.72
Quick Ratio 0.37
BMA.OL Yearly Current Assets VS Current LiabilitesBMA.OL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M 1B

More info and screens

1

3. Growth

3.1 Past

BMA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -214.78%.
The Earnings Per Share has been growing slightly by 5.82% on average over the past years.
BMA shows a decrease in Revenue. In the last year, the revenue decreased by -2.11%.
BMA shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.07% yearly.
EPS 1Y (TTM)-214.78%
EPS 3Y-21.25%
EPS 5Y5.82%
EPS Q2Q%-150%
Revenue 1Y (TTM)-2.11%
Revenue growth 3Y2.7%
Revenue growth 5Y6.07%
Sales Q2Q%7%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BMA.OL Yearly Revenue VS EstimatesBMA.OL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B 2B 2.5B
BMA.OL Yearly EPS VS EstimatesBMA.OL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

BMA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BMA.OL Price Earnings VS Forward Price EarningsBMA.OL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

BMA's Price/Free Cash Flow ratio is in line with the industry average.
Industry RankSector Rank
P/FCF 16.73
EV/EBITDA N/A
BMA.OL Per share dataBMA.OL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

BMA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BYGGMA ASA

OSL:BMA (3/7/2025, 7:00:00 PM)

16.9

-0.1 (-0.59%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryBuilding Products
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners3.19%
Ins Owner ChangeN/A
Market Cap1.18B
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.55
P/FCF 16.73
P/OCF 12.55
P/B 1.07
P/tB 1.09
EV/EBITDA N/A
EPS(TTM)-2.13
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)1.01
FCFY5.98%
OCF(TTM)1.35
OCFY7.97%
SpS30.99
BVpS15.77
TBVpS15.5
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -4.81%
ROE -13.53%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 48.29%
FCFM 3.26%
ROA(3y)8.09%
ROA(5y)6.56%
ROE(3y)23.89%
ROE(5y)17.99%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)14.21%
ROCE(5y)12.11%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-78.5%
OM growth 5Y-52.64%
PM growth 3Y-23.32%
PM growth 5Y-0.59%
GM growth 3Y-1.72%
GM growth 5Y-0.82%
F-Score4
Asset Turnover0.7
Health
Industry RankSector Rank
Debt/Equity 0.95
Debt/FCF 20.26
Debt/EBITDA N/A
Cap/Depr 19.68%
Cap/Sales 1.08%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.72
Quick Ratio 0.37
Altman-Z 1.21
F-Score4
WACC8.16%
ROIC/WACCN/A
Cap/Depr(3y)102.36%
Cap/Depr(5y)103.56%
Cap/Sales(3y)3.87%
Cap/Sales(5y)3.95%
Profit Quality(3y)109.34%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-214.78%
EPS 3Y-21.25%
EPS 5Y5.82%
EPS Q2Q%-150%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-2.11%
Revenue growth 3Y2.7%
Revenue growth 5Y6.07%
Sales Q2Q%7%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-189.07%
EBIT growth 3Y-77.92%
EBIT growth 5Y-49.76%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-63.18%
FCF growth 3Y2.49%
FCF growth 5YN/A
OCF growth 1Y-69.68%
OCF growth 3Y1.06%
OCF growth 5Y32.16%